跳至主要内容
临床试验/DRKS00010197
DRKS00010197已完成不适用

Retrospective analysis of clinical outcomes after switching from Ranibizumab to Aflibercept - Wet AMD, Aflibercept

Berner Augenklinik0 个研究点目标入组 577 人开始时间: 2016年4月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
577

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 100 Years(—)
性别
All

入选标准

  • Patients suffering from wet AMD requiring intravitreal therapy, either newly diagnosed (treatment-naive) or pretreated with Ranibizumab in case of insufficient response or other reasons.

排除标准

  • - any systemic disease potentially worsening under therapy (i.e. recent history of stroke or myocardial infarct)
  • - structural damage to the macula excluding functional gain
  • - any systemic disease interfering with local situation (i.e. Diabetes with advanced diabetic retinopathy)

研究者

发起方
Berner Augenklinik

相似试验

Retrospective analysis of clinical outcomes after... | 临床试验